Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In this issue of JAMA Psychiatry, Fervaha and colleagues1 use the publicly available database derived from 1331 patients with cognitive data in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial to explore the relationship between cognitive impairment and behaviors referred to as “amotivational.” The authors report correlations of about r = 0.30 between cognitive test performance and a cluster of items from the Heinrichs-Carpenter Quality of Life Scale that measure sense of purpose, motivation, and curiosity, which they refer to as “motivation.” The authors conclude that cognitive impairment in schizophrenia “may be partly secondary to amotivation.”
Keefe RSE. Cognition and Motivation as Treatment Targets in Schizophrenia. JAMA Psychiatry. 2014;71(9):987-988. doi:10.1001/jamapsychiatry.2014.1281